Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tecartus
Pharma
Gilead's CAR-T sales stagnate as Trodelvy takes another write-off
Gilead's CAR-Ts Yescarta and Tecartus have stayed relatively flat all year with Yescarta facing a 1% decline over the third quarter.
Zoey Becker
Nov 7, 2024 11:16am
FDA revisits CAR-T boxed warning on secondary cancers: Marks
Nov 1, 2024 10:30am
Gilead's at 'just the beginning' of cell therapy movement: exec
Feb 7, 2024 2:08pm
FDA tweaks demand for boxed warning on Gilead's CAR-T label
Jan 24, 2024 10:29am
FDA wants classwide boxed warning on existing CAR-Ts
Jan 23, 2024 3:27am
Cell therapy bigwigs endorse CAR-T in Nature Medicine article
Jan 9, 2024 5:00am
